MOTS-c

What it is

MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial DNA — specifically within the 12S ribosomal RNA gene. It is one of the family of “mitochondrial-derived peptides” (MDPs) discovered over the past decade, which has expanded understanding of mitochondrial biology beyond the traditional view of mitochondria as cellular energy producers.

MOTS-c was first characterized in 2015 by Pinchas Cohen’s laboratory at USC. The discovery added to a growing recognition that mitochondria produce signaling peptides that act on cellular metabolism, stress response, and aging-related pathways. Other mitochondrial-derived peptides include humanin and the SHLP family of peptides.

MOTS-c is not FDA-approved for any indication. It is available through licensed compounding pharmacies in the US. Clinical trials in humans are ongoing but limited; most current use is informed by extensive preclinical research and emerging early human data.

Mechanism of action

MOTS-c’s effects center on metabolic regulation and cellular stress response:

• AMPK activation: activates AMP-activated protein kinase, the master cellular energy sensor that responds to low energy states by promoting catabolic processes (glucose uptake, fatty acid oxidation) and inhibiting anabolic processes. AMPK activation is also a documented mechanism of metformin’s metabolic effects.
• Glucose homeostasis: increases insulin-stimulated glucose uptake in skeletal muscle and improves whole-body insulin sensitivity in animal models.
• Mitochondrial biogenesis: supports formation of new mitochondria and improves mitochondrial function in stressed or aged tissue.
• Folate metabolism: evidence suggests effects on the folate-methionine cycle, with implications for cellular biosynthesis and methylation.
• Exercise capacity and metabolic flexibility: animal studies show MOTS-c administration mimics some adaptive responses to exercise training.
• Anti-inflammatory effects: reduces inflammatory cytokine production in some preclinical models.
• Endogenous decline with age: circulating MOTS-c levels decline with age and inversely correlate with metabolic dysfunction markers, providing rationale for replacement-style supplementation in aging populations.

Research findings

The MOTS-c research base is substantial in preclinical models, more limited in humans:

Preclinical metabolic effects: robust evidence in rodent models for improvements in insulin sensitivity, glucose tolerance, body composition, and exercise performance. Effects span both healthy and metabolically dysfunctional animal models.

Aging models: MOTS-c administration in aged mice produces improvements in physical performance, metabolic function, and some markers of biological aging.

Diabetic models: reductions in fasting glucose and improvements in insulin sensitivity in diabetic animal models.

Mitochondrial dysfunction: protective effects in models of various mitochondrial diseases and stress conditions.

Human research: ongoing trials are exploring MOTS-c in metabolic dysfunction, type 2 diabetes, and exercise performance contexts. Early human data is encouraging but not yet sufficient for definitive clinical positioning.

The MOTS-c research has the unusual feature of strong mechanistic understanding combined with relatively recent discovery — the field is actively developing.

How we use it at The Tide

We prescribe MOTS-c selectively for patients with metabolic dysfunction features who have completed appropriate workup:

• Patients with insulin resistance who are not yet candidates for or have not adequately responded to first-line metabolic interventions
• Patients with declining exercise capacity and metabolic flexibility despite addressing foundational factors
• Patients with mitochondrial-pattern fatigue (where evaluation has ruled out other causes)
• As an adjunct to GLP-1 therapy in patients seeking additional metabolic support
• Selected patients in longevity protocols where the metabolic and mitochondrial mechanisms align with goals

Standard dosing: 5–10 mg subcutaneously, 2–3 times weekly, for 8–12 week cycles. Some protocols use daily dosing at lower amounts. We adjust based on response and tolerability.

What good response looks like: patients typically report improvements in energy, exercise performance, and recovery within 4–6 weeks. Effects on metabolic markers (glucose, insulin, lipids) emerge over the cycle. We are honest with patients that the human evidence base is still developing.

Side effects and contraindications

MOTS-c has been well-tolerated in available clinical use:

• Mild injection site reactions are most common
• Some patients report transient fatigue in the first week (paradoxical given AMPK-related mechanisms; typically resolves)
• Long-term safety data is limited — the compound has been in clinical use for relatively few years

Caution areas:

• Pregnancy and breastfeeding: avoided in absence of safety data
• Active malignancy: theoretical caution given the metabolic and mitochondrial effects, though specific concerns are not well established
• Patients on metformin or other AMPK-targeted therapies: may have additive effects requiring dose adjustment of concurrent therapies

What we don’t yet know

MOTS-c is among the more exciting peptides in current research but has not yet accumulated the clinical evidence base of more established compounds. Optimal dosing for various indications is largely empirical based on preclinical extrapolation. Long-term safety and efficacy with multi-year use is not characterized. The relative effectiveness of MOTS-c vs. established metabolic therapies (metformin, GLP-1 agonists) for specific scenarios is not well established. The role of MOTS-c in healthy adults vs. those with documented metabolic dysfunction needs better characterization. Whether MOTS-c offers benefits beyond what foundational interventions (exercise, diet, sleep) provide is an important open question. We present MOTS-c honestly to patients: an emerging peptide with strong mechanistic basis, encouraging preclinical evidence, and developing human data — used selectively in appropriate scenarios with appropriate humility about the limitations of current evidence.